Polarization effects of 4-1BB during CD28 costimulation in generating tumor-reactive T cells for cancer immunotherapy

Cancer Research

Volumn 63, Issue 10, 2003, Pages 2546-2552

  Li, Qiao ^a   Carr, Abbey ^a   Ito, Fumito ^a,b   Teitz Tennenbaum, Seagal ^a   Chang, Alfred E ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER ANTIBODY; CD137 ANTIGEN; CD28 ANTIGEN; CD3 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; MONOCLONAL ANTIBODY;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RELEASE; EFFECTOR CELL; FEMALE; LUNG METASTASIS; LYMPH NODE CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR REGRESSION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD137; ANTIGENS, CD28; CELL DIVISION; FEMALE; FIBROSARCOMA; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; IMMUNOTHERAPY, ADOPTIVE; INTERFERON TYPE II; LYMPH NODES; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; RECEPTORS, NERVE GROWTH FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR; T-LYMPHOCYTES; UP-REGULATION;

EID: 0038181099     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Rosenberg, S. A., Lotze, M. T., Muul, L. M., Chang, A. E., Avis, F. P., Linehan, W. M., and Leitman, F. P. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N. Engl. J. Med., 316: 889-897, 1987.
2. Rosenberg, S. A., Lotze, M. T., Yang, J. C., Topalian, S. L., Chang, A. E., Schwartzentruber, D. J., Aebersold, P., Leitman, S., Lineham, W. M., and Seipp, C. A. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J. Natl. Cancer Inst. (Bethesda), 85: 622-632, 1993.
3. Chang, A. E., Yoshizawa, H., Sakai, K., Cameron, M. J., Sondak, V. K., and Shu, S. Y. Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro. Cancer Res., 53: 1043-1050, 1993.
4. Plautz, G. E., Miller, D. W., Barnett, G. H., Stevens, G. H. J., Maffett, S., Kim, J., Cohen, P. A., and Shu, S. T cell adoptive immunotherapy of newly diagnosed gliomas. Clin. Cancer Res., 6: 2209-2218, 2000.
5. Plautz, G. E., Bukowski, R. M., Novick, A. C., Klein, E. A., Kursh, E. D., Olencki, T., Yetman, R. J., Pienkny, A., Sandstrom, K., and Shu, S. T-cell adoptive immunotherapy of metastatic renal cell carcinoma. Urology, 54: 617-624, 1999.
6. Lind, S. D., Tuttle, T. M., Bethke, K. P., Frank, J. L., McCrady, C. W., and Bear, H. D. Expansion and tumour specific cytokine secretion of bryostatin-activated T-cells from cyropreserved axillary lymph nodes of breast cancer patients. Surg. Onco. 2: 273-282, 1993.
7. Chang, A. E., Aruga, A., Cameron, M. J., Sondak, V. K., Normolle, D. P., Fox, B. A., and Shu, S. Y. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2. J. Clin. Oncol., 15: 796-807, 1997.
8. Yoshizawa, H., Chang, A. E., and Shu, S. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2. J. Immunol., 147: 729-737, 1991.
9. Yoshizawa, H., Chang, A. E., and Shu, S. Cellular interactions in effector cell generation and tumor regression mediated by anti-CD3/interleukin 2 activated tumor draining lymph node cells. Cancer Res., 52: 1129-1136, 1992.
10. Chang, A. E., Li, Q., Jiang, G., Sayre, D. M., Braun, T. M., and Redman, B. G. A Phase II trial of anti-CD3 activated, vaccine-primed lymphocytes in stage IV renal cell cancer. J. Clin. Oncol., 21: 884-890, 2003.
11. Schwartzentruber, D., Solomon, D., Rosenberg, S., and Topalian, S. Characterization of lymphocytes infiltrating human breast cancer: specific immune reactivity detected by measuring cytokine secretion. J. Immunother., 12: 1-12, 1992.
12. Kawakami, Y., Eliyahu, S., Sakaguchi, S., and Sakaguchi, K. Identification of the immunodominant peptides of MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. Exp. Med., 180: 347-352, 1994.
13. + T lymphocytes recognize human melanoma antigens processed and presented by Epstein-Barr virus-transformed B cells. Int. J. Cancer, 58: 69-79, 1994.
14. Topalian, S. L., Rivoltini, L., Mancini, M., Markus, N. R., Robbins, P. F., Kawakami, Y., and Rosenberg, S. A. Human CD4+ T cells specifically recognize a shared melanoma associated antigen encoded by the tyrosinase gene. Proc. Natl. Acad. Sci. USA, 91: 9461-9465, 1994.
15. Aruga, A., Aruga, E., Tanigawa, K., Bishop, D. K., Sondak, V. K., and Chang, A. E. Type 1 versus type 2 cytokine release by Vβ T cell subpopulations determines in vivo antitumor reactivity: IL-10 mediates a suppressive role. J. Immunol., 159: 664-673, 1997.
16. Hurtado, J. C., Kim, Y. J., and Kwon, B. S. Signals through 4-1BB are costimulatory to previously activated splenic T cells and inhibit activation-induced cell death. J. Immunol., 158: 2600-2609, 1997.
17. Kwon, B. S., Hurtado, J. C., Lee, Z. H., Kwack, K. B., Seo, S. K., Choi, B. K., Koller, B. H., Wolisi, G., Broxmeyer, H. E., and Vinay, D. S. Immune responses in 4-1BB (CD137)-deficient mice. J. Immunol. 168: 5483-5490, 2002.
18. Wilcox, R. A., Chapoval, A. I., Gorski, K. S., Otsuji, M., Shin, T., Flies, D. B., Tomada, K., Mittler, R. S., Tsuchiya, H., Pardoll, D. M., and Chen, L. Expression of functional CD137 receptor by dendritic cells. J. Immunol., 168: 4262-4267, 2002.
19. Takahashi, C., Mittler, R. S., and Vella, A. T. 4-1BB is a bona fide CD8 T cell survival signal. J. Immunol., 162: 5037-5040, 1999.
20. Vinay, D. S., and Kwon, B. S. Role of 4-1BB in immune responses. Semin. Immunol., 10: 481-489, 1998.
21. Cannons, J. L., Choi, Y., and Watts, T. H. Role of TNF receptor-associated factor 2 and p38 mitogen-activated protein kinase activation during 4-1BB-dependent immune response. J. Immunol., 165: 6193-6204, 2000.
22. Melero, I., Shuford, W. W., Newby, S. A., Aruffo, A., Ledbetter, J. A., Hellstrom, K. E., Mittler, R. S., and Chen, L. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat. Med., 3: 682-685, 1997.
23. Blazar, B. R., Kwon, B. S., Panoskaltsis-Mortari, A., Kwak, K. B., Peschon, J. J., and Taylor, P. A. Ligation of 4-1BB (CDw137) regulates graft-versus-host disease, grant-versus-leukemia, and graft rejection in allogeneic bone marrow transplant recipients. J. Immunol., 166: 3174-3183, 2001.
24. + Tc1 and Tc2 cells. Cell. Immunol., 192: 63-71, 1998.
25. Kim, Y-J., Kim, S. H., Mantel, P., and Kwon, B. S. Human 4-1BB regulates CD28 co-stimulation to promote Th1 cell responses. Eur. J. Immunol., 28: 881-890, 1998.
26. Barth, R. J., Bock, S. N., Mule, J. J., and Rosenberg, S. A. Unique murine tumor-associated antigens identified by tumor infiltrating lymphocytes. J. Immunol., 144: 1531-1537, 1990.
27. Aruga, A., Aruga, E., Cameron, M. J., and Chang, A. E. Different cytokine profiles released by CD4+ and CD8+ tumor-draining lymph node cells involved in mediating tumor regression. J. Leukocyte Biol., 61: 1-10, 1997.
28. Kim, J. A., Averbook, B. J., Chambers, K., Rothchild, K., Kjaergaard, J., Papay, R., and Shu, S. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation. Cancer Res., 61: 2031-2037, 2001.
29. Wilcox, R., Flies, D., Zhu, G., Johnson, A., Tamada, K., Chapoval, A., Strome, S., Pease, L., and Chen, L. Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. Clin. Investig., 109: 651-659, 2002.
30. Strome, S. E., Martin, B., Flies, D., Tamada, K., Chapoval, A. I., Sargent, D. J., Shu, S., and Chen, L. Enhanced therapeutic potential of adoptive immunotherapy by in vitro CD28/4-1BB costimulation of tumor-reactive T cells against poorly immunogenic, major histocompatibility complex class I-negatives A9P melanoma. J. Immunother., 23: 430-437, 2000.
31. Li, Q., Yu, B., Grover, A., Zeng, X., Takeshita, N., and Chang, A. E. Therapeutic effects of tumor reactive CD4+ cells generated from tumor-primed lymph nodes using anti-CD/anti-CD28 monoclonal antibodies. J. Immunother., 25(4): 304-313, 2002.
32. Maus, M. V., Thomas, A. K., Leonard, D. G. B., Allman, D., Addya, K., Schlienger, K., Riley, J. L., and June, C. H. Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor CD28 and 4-1BB. Nat. Biotechnol., 20: 143-148, 2002.